In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report), with ...

Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target ...

Le chanteur du groupe «Les Frères à Ch’val», Polo Bellemare, s’est éteint à 68 ans après avoir eu recours à l’aide médicale à ...

En conclusion, la réitération par Oppenheimer de la note "Surperformance" et de l’objectif de 22$ reflète la confiance dans la stratégie commerciale d’Avadel Pharmaceuticals. Se négociant à 7,82$, ...

Additionally, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics from Perform to Outperform, setting a price target of $4.00, citing renewed confidence in the company’s pipeline. The ...

Additionally, Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics from Perform to Outperform, setting a price target of $4.00, citing renewed confidence in the company’s pipeline.

Le 26 février 2025, Rona Jeffrey A, Directeur des Affaires et des Finances (CBFO) d’ Ovid Therapeutics Inc . (NASDAQ:OVID), a vendu 3.902 actions ordinaires de la société. Les actions ont été vendues ...

Your next question is from the line of Francois Brisebois with Oppenheimer. There is no response from Francois' line. We'll go to the next question. Patrick Trucchio with H.C. Thanks. Good morning.

Your next question is from the line of François Brisebois with Oppenheimer. François, your line is open. Please make sure you do not have yourself on mute. There is no response from François' line.